Navigation Links
SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Date:9/23/2009

SAN FRANCISCO, CA SEPTEMBER 23, 2009 Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

Unlike similar prior studies (SPIRIT FIRST, SPIRIT II and SPIRIT III), the SPIRIT-IV trial was powered for superiority for clinical endpoints without angiographic follow up.

The trial also examined the differences in performance of the two stents in patients with diabetes.

"The results with the everolimus stent demonstrate enhanced safety and efficacy compared to the paclitaxel stent in this large-scale study without routine angiographic follow-up and sets a new standard for event-free survival after [implantation of a drug-eluting stent]," said principal investigator Gregg W. Stone, MD, immediate past chairman of CRF, professor of medicine at Columbia University Hospital and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center.

Results of the study were presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The primary endpoint of the trial was target lesion failure (TLF) at one year, a composite measure of cardiac death, target vessel heart attack or ischemia-driven target lesion revascularization (TLR). Major secondary endpoints of the trial were TLR at one year, and a composite of cardiac death or target vessel heart attack at one year.

For the everolimus stent, TLF at one year was 4.2 percent, and for the paclitaxel-eluting stent, TLF was 6.8 percent, a signific
'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Boston Scientific PROMUS(R) and First-Generation TAXUS(R) Express(R) Stents Continue Excellent Performance in SPIRIT III Trial
2. The Celebrate Wellness Expo Presents Motivational Speaker & Author Dr. Robin L. Smith and Spiritual Teacher & Author Rev. Michael Bernard Beckwith
3. ColorAlchemy Hosts YouTube Mini-workshop Video About How Light and the Color Green Instantly Helps Balance Mind, Body, and Spirit
4. Honor Spirit and Memory of a Special Pet During National Pet Memorial Month
5. Atlanta Cosmetic Plastic Surgeon Thomas Lintner, MD Renewing Bodies and Spirits for New Moms with a Mommy Makeover
6. Spirituality and Medicine: Can the Two Walk Together?
7. Spiritual Outlook Can Affect Mental Health in Breast Cancer
8. Wounded Warrior Project (WWP) Seeks to Provide Mind, Body and Spirit Healing for Combat Stress
9. Provocative New Nonfiction Addresses Spiritual Destiny
10. 2009 ISSSEEM Conference to Have Deepak Chopra Discuss Bridging Science and Spirit
11. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Daily Gossip indicates in its ... easily. A panic attack is a feeling of intense stress ... are a series of symptoms that sufferers commonly deal with ... of breath, stress or anxiety. Naturally, panic attacks deeply affect ... way to overcome them. , The 60 Second Panic Solution ...
(Date:7/30/2014)... The Restore My Blood Sugar review recently ... sugar levels can now find an amazingly successful method of ... was created by D. Chao and Andrew Forester who claim ... when it comes to normalizing blood sugar levels. Chao actually ... secret to the cure of diabetes that all patients should ...
(Date:7/30/2014)... 30, 2014 Within weeks freshman will begin to ... Each hopes this will be a time of growth and the ... to pause; it may not be as easy as it looks. ... will switch their major at least once and many will switch ... and the costs are exacerbated when switching in the later years ...
(Date:7/30/2014)... July 30, 2014 Ticket Down ... Bayern Munich vs. Chivas Guadalajara friendly exhibition match at ... World Cup, the one team that was left standing as ... made it through the world’s largest football competition and even ... their way to the cup. Germany was led by seven ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... to develop dementia, but researchers have been unable to explain ... Specifically, they haven,t been able to figure out the direction ... on dementia, or does dementia cause people to become depressed? ... journal Neurology sheds more light on the mystery. ...
Breaking Medicine News(10 mins):Health News:60 Second Panic Solution Review Reveals Unique Way to Stop Panic Attacks 2Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... 16 A grassroots,effort to promote advance care planning ... than 450 participating organizations in,all 50 states. The first ... a year ago and implemented with no budget or,full-time ... am blown away by the response to our grassroots ...
... know anyone,who,s a Type-A personality? A multi-tasking, go-getter? ... would turn out to be Type-A.,There,s a lot ... But the antioxidants,deserve some special attention., (Photo: ... food by their deep-colored pigment - such as ...
... thinking skills, study finds , , WEDNESDAY, April 16 (HealthDay News) ... than women to develop mild cognitive impairment, new research shows. ... found more women than men [or an equal proportion] have ... men," study author Rosebud Roberts, of the Mayo Clinic in ...
... Abstract 19, Study highlights:, -- Low ... prevalence,of peripheral arterial disease (PAD) in a study that ... feel this needs further study and do not recommend,people ... by,their doctors., -- The American Heart Association recommends ...
... patient care while ... saving Medicaid dollars, ... Best Practices in Consumer Empowerment and,Protection Awards competition, naming the ... Eli Lilly,and Company as Silver Award winners in the Health ...
... Challenges Facing the ... Healthcare Industry, ... association with U.S. News & World Report,hosted an exclusive panel ... the National Press Club in Washington, D.C.,The event, attended by ...
Cached Medicine News:Health News:More Than 350 Events Today in Recognition of First National Healthcare Decisions Day 2Health News:Cranberries: The Little Fruit With a Great Big Punch 2Health News:Cranberries: The Little Fruit With a Great Big Punch 3Health News:Low Vitamin D Levels Associated With an Increased Risk of Peripheral Arterial Disease 2Health News:Low Vitamin D Levels Associated With an Increased Risk of Peripheral Arterial Disease 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 4Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3
(Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
(Date:7/30/2014)... , July 30, 2014  DigiPath, Inc. (OTCBB ... is expanding into the cannabis testing and education markets, ... its business and affairs not previously disclosed or, to ... recent unusual market action. "We have noticed ... the last three trading days," said Steve Barbee ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... Jan. 5, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... Phase 1 study with ISIS-TTRRx.  The results demonstrated ... reductions of greater than 80 percent in transthyretin ... well tolerated with no significant adverse events.  ISIS-TTRRx ...
... (NASDAQ: AMRI ), a global contract services ... preferred provider agreement with BioPontis Alliance LLC. The agreement ... gap between early-stage research and technologies being discovered and ... provide its services in small molecule discovery, development, and ...
Cached Medicine Technology:ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 2ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 3ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 4AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 2AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC 3
Inquire...
Bench Top Class I Containment Cabinet Personnel Protection...
Inquire...
... internal calibration mass for convenient ... of Fully Automatic Self-Calibration at ... changes are detected, or touch-key ... RS232 Interface, Shimadzu WindowsDirect communication ...
Medicine Products: